Corbus Pharmaceuticals' Last Participant Completes Last Clinical Visit In Its CANYON-1 Phase 1b Clinical Study Of CRB-913 To Treat Obesity
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced the last patient has completed their last clinical visit ("Last
Corbus finished testing a new obesity medicine on real people—a big milestone that means they can now look at all the data to see if it worked. When a company completes patient testing, watch to see if the results are strong enough for the next steps toward approval.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.